TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

O Türeci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.